MA33064B1 - Systemes à base de conjugués pour administration contrôlée de médicaments - Google Patents

Systemes à base de conjugués pour administration contrôlée de médicaments

Info

Publication number
MA33064B1
MA33064B1 MA34121A MA34121A MA33064B1 MA 33064 B1 MA33064 B1 MA 33064B1 MA 34121 A MA34121 A MA 34121A MA 34121 A MA34121 A MA 34121A MA 33064 B1 MA33064 B1 MA 33064B1
Authority
MA
Morocco
Prior art keywords
management system
control management
concomitant drug
drug control
conjugates
Prior art date
Application number
MA34121A
Other languages
Arabic (ar)
English (en)
Inventor
Todd C Zion
Thomas M Lancaster
Original Assignee
Smartcells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smartcells Inc filed Critical Smartcells Inc
Publication of MA33064B1 publication Critical patent/MA33064B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des conjugués qui comprennent un médicamentset un ligand qui comprend un premier saccharide. Le conjugué est caractérisé en ce que, lorsqu'il est administré à un mammifère, au moins une propriété pharmacocinétique ou pharmacodynamique de celui-ci est sensible à la concentration de sérum d'un second saccharide. Outre des procédés d'utilisation et de préparation de ces conjugués, l'invention concerne également des exemples de conjugués et des formulations à libération prolongée.
MA34121A 2009-01-28 2010-01-27 Systemes à base de conjugués pour administration contrôlée de médicaments MA33064B1 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US14787809P 2009-01-28 2009-01-28
US15964309P 2009-03-12 2009-03-12
US16210709P 2009-03-20 2009-03-20
US16308409P 2009-03-25 2009-03-25
US21989709P 2009-06-24 2009-06-24
US22357209P 2009-07-07 2009-07-07
US25285709P 2009-10-19 2009-10-19
PCT/US2010/022268 WO2010088294A1 (fr) 2009-01-28 2010-01-27 Systèmes à base de conjugués pour administration contrôlée de médicaments

Publications (1)

Publication Number Publication Date
MA33064B1 true MA33064B1 (fr) 2012-02-01

Family

ID=42395986

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34121A MA33064B1 (fr) 2009-01-28 2010-01-27 Systemes à base de conjugués pour administration contrôlée de médicaments

Country Status (24)

Country Link
US (5) US9050370B2 (fr)
EP (1) EP2391218B1 (fr)
JP (3) JP5508438B2 (fr)
KR (2) KR20110104081A (fr)
CN (2) CN102365025A (fr)
AU (2) AU2015202871B2 (fr)
BR (1) BRPI1007457A2 (fr)
CA (2) CA2932926C (fr)
CO (1) CO6400173A2 (fr)
CR (1) CR20110408A (fr)
DO (1) DOP2011000244A (fr)
EA (1) EA027757B1 (fr)
EC (1) ECSP11011240A (fr)
ES (1) ES2791683T3 (fr)
GT (1) GT201100208A (fr)
IL (1) IL214099A0 (fr)
MA (1) MA33064B1 (fr)
MX (1) MX2011007929A (fr)
NI (1) NI201100150A (fr)
NZ (1) NZ594248A (fr)
PE (1) PE20120583A1 (fr)
SG (3) SG173112A1 (fr)
TN (1) TN2011000354A1 (fr)
WO (1) WO2010088294A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
WO2010088268A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Matériaux à libération contrôlée déclenchée de façon exogène et leurs utilisations
US9050370B2 (en) * 2009-01-28 2015-06-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
WO2010107519A1 (fr) 2009-03-20 2010-09-23 Smartcells, Inc. Conjugués fonctionnalisés aux extrémités et leurs utilisations
US9095623B2 (en) 2009-03-20 2015-08-04 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
AU2011282977A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AU2011282983A1 (en) * 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
CA2805902A1 (fr) 2010-07-28 2012-02-02 Smartcells, Inc. Lectines recombinees, lectines a site de liaison modifie et leurs utilisations
WO2012015692A2 (fr) 2010-07-28 2012-02-02 Smartcells, Inc. Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci
WO2012050822A1 (fr) * 2010-10-14 2012-04-19 Smartcells, Inc. Utilisations de récepteur du mannose des macrophages (mmr) pour cribler des composés et utilisations de ces composés
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
TWI439288B (zh) * 2012-10-05 2014-06-01 Univ China Medical 藥用載體及其製備方法與用途
JP6445453B2 (ja) * 2012-11-28 2018-12-26 ビクトリア リンク リミテッド 樹状コア化合物
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
CA2937532A1 (fr) * 2013-01-22 2014-07-31 Case Western Reserve University Analogues d'insuline tronques a leur extremite n-terminale
US9884125B2 (en) * 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3280450A4 (fr) * 2015-04-08 2018-12-12 Merck Sharp & Dohme Corp. Conjugués d'insuline sensibles au glucose
BR112018074716A2 (pt) 2016-06-02 2019-03-12 Sanofi conjugados de um agente farmacêutico e porção capaz de ligar-se a uma proteína sensível à glicose
WO2018136505A1 (fr) 2017-01-17 2018-07-26 Wayne State University Compositions de polymère zwitterionique-insuline et procédés associés
EP3600381A4 (fr) * 2017-03-23 2021-06-16 Merck Sharp & Dohme Corp. Insuline sensible au glucose comprenant un groupe de sucre trivalent pour le traitement du diabète
AU2017405304B2 (en) * 2017-03-23 2022-03-03 Victoria Link Limited Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses
KR20200095507A (ko) 2017-12-01 2020-08-10 사노피 글루코오스 감지 단백질에 결합할 수 있는 모이어티 및 약제의 신규 접합체
WO2019125878A1 (fr) * 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
CN108610494B (zh) * 2018-03-20 2020-11-06 南京理工大学 聚醚砜/功能性含糖聚合物杂化膜的制备方法
CN110146605A (zh) * 2019-04-19 2019-08-20 南通联亚药业有限公司 一种测定格列吡嗪原料药及其缓释片中特定基因毒性杂质的分析方法
WO2020247297A1 (fr) 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. Conjugués d'insuline sensibles au glucose
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
CN112480184A (zh) * 2020-12-09 2021-03-12 上海应用技术大学 一种利用梯度点击化学合成含多种糖的树枝化糖胺的方法
WO2022234030A1 (fr) 2021-05-05 2022-11-10 Novo Nordisk A/S Insuline active (iob) pour insuline sensible au glucose
EP4613738A1 (fr) * 2022-11-01 2025-09-10 Samyang Holdings Corporation Lipide ayant des groupes fonctionnels amides et esters, et son procédé de production
CA3271735A1 (fr) * 2022-11-16 2025-05-20 Samyang Holdings Corporation Composition de nanoparticule pour l’administration de médicament

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39055A (en) 1863-06-30 Improvement in churns
US3591574A (en) 1968-05-29 1971-07-06 American Home Prod Tri-n-phenylglycyl derivatives of insulin
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
US3847890A (en) 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
US4377567A (en) 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
DE2964024D1 (en) 1978-10-02 1982-12-16 Procter & Gamble Liposomes for drug delivery and composition containing a liposome drug system
US4348387A (en) 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
JPS608000B2 (ja) 1980-04-11 1985-02-28 呉羽化学工業株式会社 アミノフエニル誘導体及び該誘導体を含有する生理活性剤
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4498843A (en) 1982-08-02 1985-02-12 Schneider Philip H Insulin infusion pump
US4444683A (en) 1982-11-17 1984-04-24 University Of Utah Glycosylated insulin derivatives
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
EP0119650A3 (fr) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Conjugués de galactosyl-insuline utilisés dans le traitement des diabétiques
US4863896A (en) 1984-05-03 1989-09-05 Technology Unlimited, Inc. Diabetic control by combined insulin forms
DK160633C (da) 1985-05-15 1991-09-02 Henning Munk Ejlersen Slangepumpe, isaer til avendelse som insulinpumpe
US5395924A (en) 1986-03-20 1995-03-07 Dana-Farber Cancer Institute, Inc. Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity
US5239062A (en) 1986-03-20 1993-08-24 Dana-Farber Cancer Institute, Inc. Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US5062841A (en) 1988-08-12 1991-11-05 The Regents Of The University Of California Implantable, self-regulating mechanochemical insulin pump
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
RU2003351C1 (ru) * 1991-06-26 1993-11-30 Липов Борис Петрович; Сафронов Игорь Николаевич Инъектор
GB9200638D0 (en) 1992-01-10 1992-03-11 Leicester Polytechnic Drug system
DE69328523T2 (de) 1992-02-13 2000-09-21 Surmodics, Inc. Immobilisierung eines chemischen spezies in einer vernetzten matrix
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
GB9313484D0 (en) 1993-06-30 1993-08-11 Univ Montfort Drug system ii
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
SI0792290T1 (en) 1993-09-17 2001-12-31 Novo Nordisk As Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
JP2000501414A (ja) 1995-11-22 2000-02-08 ザ・ジョンズ・ホプキンス・ユニバーシティー 生体分子の細胞取り込みを高めるリガンド
US5723589A (en) 1995-12-21 1998-03-03 Icn Pharmaceuticals Carbohydrate conjugated bio-active compounds
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
EP0954589A1 (fr) 1997-01-24 1999-11-10 Novo Nordisk A/S Nouvelles sequences-guides synthetiques de peptides
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
SV1998000125A (es) 1997-10-24 1999-05-24 Lilly Co Eli Composiciones de insulina insoluble ref. x-11232
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1044016B1 (fr) 1998-01-09 2005-03-16 Novo Nordisk A/S Compositions d'insuline stabilisees
EP1071703B1 (fr) 1998-04-15 2005-07-20 Novo Nordisk A/S NOUVEAU PROCEDE DE SEPARATION DE PROTEINES AU MOYEN D'UN ELUANT RENFERMANT DES IONS Ca++
US6300319B1 (en) * 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US6844166B1 (en) 1998-09-11 2005-01-18 Sensor Technologies Inc. Recombinant reduced valency carbohydrate binding ligands
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6521738B2 (en) 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
US6777207B2 (en) 1999-12-29 2004-08-17 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
EP1290024A1 (fr) * 2000-06-02 2003-03-12 Novo Nordisk A/S Liberation glucose-dependante d'insuline par des derives d'insuline detectant le glucose
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US6650951B1 (en) 2000-06-19 2003-11-18 International Business Machines Corporation Method and insulin pump for providing a forgotten bolus warning
EP1301585A2 (fr) 2000-07-13 2003-04-16 The Ohio State University Research Foundation Biopolymeres multimeres en tant qu'elements structurels, detecteurs et actionneurs dans des microsystemes
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020192182A1 (en) 2001-03-12 2002-12-19 Stephen Massia Polysaccharide-based polymerizable hydrogels
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
EP2305312B1 (fr) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
EP1446163A4 (fr) 2001-10-26 2006-01-04 Uab Research Foundation Conjugues multimedicaments multiligands permettant une administration ciblee de medicaments
US6736796B2 (en) 2001-11-26 2004-05-18 Nili-Med Ltd. Fluid drug delivery device
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
WO2003048195A2 (fr) * 2001-12-02 2003-06-12 Novo Nordisk A/S Nouvelles insulines gluco-dependantes
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
EP1452950A4 (fr) 2001-12-07 2009-07-08 Ntt Docomo Inc Terminal de communication mobile, procede permettant de commander l'etat d'execution d'un programme d'application, programme d'application et support d'enregistrement sur lequel le programme d'application est enregistre
US6744350B2 (en) 2002-02-28 2004-06-01 Smiths Medical Md, Inc. Insulin pump having missed meal bolus alarm
US6852104B2 (en) 2002-02-28 2005-02-08 Smiths Medical Md, Inc. Programmable insulin pump
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
EP1545462A4 (fr) * 2002-07-19 2007-08-08 Univ California Dendrimeres servant de translocateurs moleculaires
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
WO2004039373A1 (fr) * 2002-10-29 2004-05-13 Ranbaxy Laboratories Limited Derives d'iminosucres utilises comme inhibiteurs de la glucosidase
CA2509382A1 (fr) 2002-12-17 2004-07-08 Todd C. Zion Systemes reagissant a des stimulis pour l'administration regulee de medicaments
WO2004057002A2 (fr) 2002-12-20 2004-07-08 Greenovation Biotech Gmbh Ameliorations apportees ou associees a la production de proteines
JPWO2004101619A1 (ja) * 2003-05-15 2006-10-26 塩野義製薬株式会社 機能的糖ペプチドの合理的設計および合成
EP1687428A1 (fr) 2003-11-14 2006-08-09 Novo Nordisk A/S Procede de fabrication d'insuline acylee
US20080102114A1 (en) 2004-04-23 2008-05-01 Panduranga Rao Koritala Microparticles and Nanoparticles for the Transmucosal Delivery of Therapeutic and Diagnostic Agents
WO2006008238A1 (fr) 2004-07-16 2006-01-26 Novo Nordisk A/S Procede d'acylation selective
MX2007000883A (es) 2004-07-19 2007-04-02 Biocon Ltd Conjugados de insulina-oligomero, formulaciones y usos de los mismos.
WO2006062685A2 (fr) * 2004-11-11 2006-06-15 Affymax, Inc. Nouveaux peptides se liant au recepteur de l'erythropoietine
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20060247154A1 (en) 2005-02-24 2006-11-02 Lifescan, Inc. Concanavalin a, methods of expressing, purifying and characterizing concanavalina, and sensors including the same
US20070207498A1 (en) 2005-02-24 2007-09-06 Lifescan, Inc. Design and construction of dimeric concanavalin a mutants
WO2006102762A1 (fr) 2005-04-01 2006-10-05 Mcmaster University Microgels reagissant au glucose
CA2622352C (fr) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Composes pyrazole substitues
JP2009511544A (ja) 2005-10-10 2009-03-19 ナームローゼ・フエンノートチヤツプ・オルガノン 抗血栓化合物
US7517856B2 (en) 2005-10-11 2009-04-14 Ben-Gurion University Of The Negev Research And Development Authority Bioconjugates comprising sulfated polysaccharides and their uses
WO2007047922A2 (fr) * 2005-10-19 2007-04-26 Smartcells, Inc. Conjugues polymeres-medicaments
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
US20100189643A1 (en) 2006-07-24 2010-07-29 Duke University Drug delivery with stimulus responsive biopolymers
JP2009544680A (ja) 2006-07-25 2009-12-17 リポクセン テクノロジーズ リミテッド ポリサッカライドによるタンパク質のｎ末端誘導体化
FR2904315B1 (fr) 2006-07-26 2012-12-14 Centre Nat Rech Scient Composes pyridaziniques et pyrroliques, procedes d'obtention et applications
US20080172028A1 (en) 2006-10-17 2008-07-17 Blomquist Michael L Insulin pump having selectable insulin absorption models
US7515060B2 (en) 2006-10-17 2009-04-07 Smiths Medical Md, Inc. Insulin pump for the visually impaired
CN101273961A (zh) 2007-03-30 2008-10-01 中国人民解放军总医院 葡萄糖敏感水凝胶
US20090053167A1 (en) 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
US20090005726A1 (en) 2007-06-27 2009-01-01 Steven Paul Jones Insulin Pump Having Expected Bolus Interval and an Early Bolus Interval
WO2009033588A2 (fr) 2007-09-11 2009-03-19 F. Hoffmann-La-Roche Ag Système d'administration auto-contrôlée d'insuline
WO2009059450A1 (fr) 2007-11-05 2009-05-14 Shanghai Jiaotong University Administration de médicament dirigée par un ligand peptidique
GB2446247B (en) 2007-11-27 2008-12-17 Robert Joseph Wagener Homeostatic insulin pump
WO2009089396A2 (fr) 2008-01-08 2009-07-16 Neose Technologies, Inc. Glycoconjugaison de polypeptides employant des oligosaccharyltransférases
US20090177154A1 (en) 2008-01-08 2009-07-09 Michael Blomquist Insulin pump with convenience features
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
RU2381238C2 (ru) 2008-01-31 2010-02-10 Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (статус государственного учреждения) Способ получения глюкозочувствительных полимерных гидрогелей
EP2242767A4 (fr) 2008-02-19 2011-04-06 Biocon Ltd Procédé d'obtention d'insulines hétérologues purifiées s'exprimant dans des levures
DK2141620T3 (en) 2008-07-01 2019-02-18 Hoffmann La Roche Insulin pump and method for controlling one of the insulin pump's user interface
EP2391215A4 (fr) * 2009-01-28 2013-10-30 Smartcells Inc Lectines de site de liaison modifiées et usage correspondant
US8940690B2 (en) * 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
WO2010088268A1 (fr) * 2009-01-28 2010-08-05 Smartcells, Inc. Matériaux à libération contrôlée déclenchée de façon exogène et leurs utilisations
US9050370B2 (en) * 2009-01-28 2015-06-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
CA2750245A1 (fr) * 2009-01-28 2010-08-05 Smartcells, Inc. Matieres reticulees a base d'aptameres polynucleotidiques et leurs utilisations
BRPI1007466A2 (pt) * 2009-01-28 2018-06-12 Smartcells Inc conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
US9095623B2 (en) * 2009-03-20 2015-08-04 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010107519A1 (fr) * 2009-03-20 2010-09-23 Smartcells, Inc. Conjugués fonctionnalisés aux extrémités et leurs utilisations
EP2408470A4 (fr) * 2009-03-20 2012-08-29 Smartcells Inc Conjugués d'insulines non déposées solubles et leurs utilisations
EP2448962B1 (fr) 2009-06-30 2016-10-19 Novo Nordisk A/S Dérivés d'insuline
AU2011282983A1 (en) * 2010-07-28 2013-02-21 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
CA2805902A1 (fr) * 2010-07-28 2012-02-02 Smartcells, Inc. Lectines recombinees, lectines a site de liaison modifie et leurs utilisations
WO2012015692A2 (fr) * 2010-07-28 2012-02-02 Smartcells, Inc. Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci
US9884125B2 (en) * 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3280450A4 (fr) * 2015-04-08 2018-12-12 Merck Sharp & Dohme Corp. Conjugués d'insuline sensibles au glucose
US9899205B2 (en) * 2016-05-25 2018-02-20 Kla-Tencor Corporation System and method for inhibiting VUV radiative emission of a laser-sustained plasma source

Also Published As

Publication number Publication date
KR101635689B1 (ko) 2016-07-01
CA2932926A1 (fr) 2010-08-05
US20110301083A1 (en) 2011-12-08
JP6040301B2 (ja) 2016-12-07
MX2011007929A (es) 2011-08-17
SG193837A1 (en) 2013-10-30
JP2014139215A (ja) 2014-07-31
ES2791683T3 (es) 2020-11-05
NZ594248A (en) 2015-03-27
ECSP11011240A (es) 2011-11-30
EP2391218A1 (fr) 2011-12-07
JP5834103B2 (ja) 2015-12-16
US9050370B2 (en) 2015-06-09
CA2932926C (fr) 2018-12-18
AU2010208313A8 (en) 2015-12-17
US20180064824A1 (en) 2018-03-08
CA2750262C (fr) 2016-08-09
AU2010208313B2 (en) 2015-07-23
JP2012516341A (ja) 2012-07-19
DOP2011000244A (es) 2011-10-15
US20150265717A1 (en) 2015-09-24
KR20110104081A (ko) 2011-09-21
AU2015202871A1 (en) 2015-06-18
EP2391218A4 (fr) 2015-05-13
US9265838B2 (en) 2016-02-23
US10398781B2 (en) 2019-09-03
EA201170986A1 (ru) 2012-03-30
SG2014006597A (en) 2014-04-28
NI201100150A (es) 2011-11-09
WO2010088294A1 (fr) 2010-08-05
EA027757B1 (ru) 2017-08-31
CN102365025A (zh) 2012-02-29
KR20140012219A (ko) 2014-01-29
BRPI1007457A2 (pt) 2015-08-25
CA2750262A1 (fr) 2010-08-05
US20140274888A1 (en) 2014-09-18
AU2015202872B2 (en) 2017-05-25
GT201100208A (es) 2014-02-10
JP2016065072A (ja) 2016-04-28
US20160193351A1 (en) 2016-07-07
AU2015202871B2 (en) 2017-08-17
CO6400173A2 (es) 2012-03-15
SG173112A1 (en) 2011-08-29
TN2011000354A1 (en) 2013-03-27
CN105753965A (zh) 2016-07-13
US9579391B2 (en) 2017-02-28
AU2015202872A1 (en) 2015-06-18
PE20120583A1 (es) 2012-05-19
CR20110408A (es) 2011-12-08
EP2391218B1 (fr) 2020-03-18
AU2010208313A1 (en) 2011-09-01
JP5508438B2 (ja) 2014-05-28
IL214099A0 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
MA33064B1 (fr) Systemes à base de conjugués pour administration contrôlée de médicaments
Yonemori et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin
FR17C1057I1 (fr) Anticorps diriges contre le recepteur de l'il-6 humaine, a affinite elevee pour ledit recepteur
EP1858926A4 (fr) Glycosaminoglycanases solubles et procédés de préparation et d'utilisation de glycosaminoglycanases solubles
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA29662B1 (fr) Compositions pour l'apport de medicaments hautement solubles dans l'eau
EP2094307A4 (fr) Tes7, et anticorps se liant à celui-ci
CY1119342T1 (el) Τριμερης πρωτεϊνη συντηξης οχ40-ανοσοσφαιρινης και μεθοδοι χρησης
ATE480524T1 (de) Pyridazinonderivate als schilddrüsenhormon- rezeptoragonisten
WO2006128167A3 (fr) Detection de cellules et de compositions par tomographie par coherence optique
WO2007116300A3 (fr) Cintre de vetement a pince de maintien pourvu de patins de friction modulaires
BRPI0719037B8 (pt) sistema extravascular para acessar a vasculatura de um paciente e método para fabricar o mesmo
BRPI0514474A (pt) multiparticulados
AU2003249551A1 (en) System for in vivo sampling and analysis
WO2008154590A3 (fr) Prédiction de la réactivité au témozolomide
FR2935352B1 (fr) Roulette d'allegement pour marchandises
TNSN08152A1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation
EP2086138A4 (fr) Dispositif de relais et système de diffusion à l'aide de celui-ci
Cutolo et al. Presence of estrogen receptors in human myeloid monocytic cells (THP-1 cell line)
WO2008035229A3 (fr) Compositions et procédés d'administration de médicament ciblée par rapport au ph
WO2008005050A3 (fr) Fauteuil releveur et structure de base d'une chaise comprenant un mécanisme d'équilibrage des forces destiné à être utilisé dans ledit dispositif
EP2365002A3 (fr) Composition pour le traitement d'une pathologie associée à la MSRV/HERV-W
PE20070622A1 (es) Administracion de inhibidores de dipeptidil peptidasa
WO2003017938A3 (fr) Conjugue cibles sur des recepteurs cibles
EP1951290A4 (fr) Agent pour utilisation dans le cas d'intolerance au fructose